If you're a qualified researcher comparing AOD-9604 peptide to structurally related compounds like HGH Fragment 176-191, the distinctions in sequence, analytical documentation, and sourcing standards matter enormously. I'm a peptide quality specialist at PeptideValidation.com, and I've spent years reviewing COAs, HPLC traces, and vendor credentials so that laboratories get the materials their protocols actually require. This guide breaks down the key differences in plain language so your procurement decisions rest on solid analytical ground.

What Is AOD-9604 Peptide? A Quick Definition

AOD-9604 peptide is a synthetic 16-amino-acid fragment derived from human growth hormone (hGH), specifically the C-terminal region spanning positions 176 to 191, with a tyrosine residue added at position 176 and a disulfide bridge between Cys182 and Cys189. It is studied in controlled laboratory settings for its molecular interactions related to lipid metabolism pathways.

AOD-9604 is sometimes written as 'Advanced Obesity Drug 9604,' because that was its original research designation at Monash University in the early 2000s. The compound shares partial sequence identity with HGH Fragment 176-191 but carries a critical structural modification: an added tyrosine residue at the N-terminus that changes its molecular weight from roughly 1,815 Da to approximately 1,978 Da.

That ~163 Da difference is not cosmetic. It affects how mass spectrometry (MS) confirms identity, which means a COA written for HGH Fragment 176-191 cannot be applied to AOD-9604, even if the two compounds look similar on paper. Honest, I've seen labs mix them up and waste months of experimental data as a result.

At PeptideValidation.com, we supply AOD-9604 as a 2 mg lyophilized powder. Lyophilization removes moisture under vacuum, which stabilizes the peptide backbone and keeps the disulfide bridge intact during shipping and storage. That format gives laboratories a consistent starting mass when reconstituting for each experimental run, which matters a lot when you're trying to reproduce results across batches.

For a broader overview of how AOD-9604 peptide fits into the wider growth hormone fragment literature, see our complete AOD-9604 research guide.

AOD-9604 vs HGH Fragment 176-191: Structural Comparison

The key structural differences between AOD-9604 and HGH Fragment 176-191 are:

1. AOD-9604 includes an N-terminal tyrosine residue; HGH Fragment 176-191 does not.
2. Molecular weight: ~1,978 Da (AOD-9604) vs ~1,815 Da (HGH Fragment 176-191).
3. Both share a conserved Cys182-Cys189 disulfide bridge.
4. Identity confirmation requires compound-specific MS reference values for each.

Because the two peptides overlap so heavily in sequence, researchers sometimes assume their analytical methods are interchangeable. They are not. Here is where the differences become practically important.

Sequence identity. AOD-9604 is Tyr-hGH(176-191), meaning the 16-amino-acid core is prefixed by tyrosine. HGH Fragment 176-191 starts directly at position 176 without that addition. When you run reversed-phase HPLC, both compounds elute at similar retention times, which is exactly why mass spectrometry identity confirmation is non-negotiable for either peptide.

Molecular weight and MS fingerprint. A correctly calibrated electrospray ionization MS system should detect AOD-9604 at [M+H]+ of approximately 1,979.2 and HGH Fragment 176-191 at approximately 1,816.1. If a COA for 'AOD-9604 peptide' shows a mass closer to 1,816, you are almost certainly looking at the wrong compound or a mislabeled batch.

Disulfide bridge stability. Both compounds contain a disulfide bridge between cysteine residues. Lyophilized storage below -20 degrees Celsius helps preserve this bond. Peptides stored in aqueous solution at room temperature risk partial oxidation, scrambled disulfide formation, and dimer artifacts that inflate apparent purity on HPLC.

What this means for your COA review. Any batch-specific COA you receive should specify the compound name, the correct MW, the HPLC purity percentage, and the MS confirmation value. If those four elements do not match the expected parameters for AOD-9604, reject the lot before it enters your workflow.

How to Read a COA for AOD-9604 Peptide

A valid COA for AOD-9604 peptide must include: compound name with CAS or sequence identifier, molecular weight confirmed by mass spectrometry, HPLC purity (ideally ≥98%), batch/lot number, manufacture and expiry dates, and storage recommendations. Missing any of these fields is a red flag that warrants follow-up before the material enters your protocol.

Reviewing a COA sounds routine, but I've found that even experienced researchers sometimes gloss over the details that protect their data. Let me walk you through the fields that matter most.

Compound identification. The COA should state 'AOD-9604' or 'Tyr-hGH(176-191)' explicitly. Vague labels like 'growth hormone peptide' or 'GH fragment' indicate the vendor is not distinguishing between related compounds.

HPLC purity. Most reputable peptide suppliers report purity by area-under-the-curve (AUC) from a reversed-phase C18 column run. Research-grade material typically targets 98% or above. Anything below 95% should prompt you to ask for the full chromatogram, not just the summary figure.

Mass spectrometry confirmation. Look for the observed [M+H]+ or [M+2H]2+ ion, not just a statement that 'MS confirms identity.' A COA that only says 'MS: pass' without a numerical value is using MS as a checkbox, not as a real analytical tool.

Batch traceability. Each lot should carry a unique identifier. Since you should be able to request the raw data behind any COA, that lot number is your audit trail. Labs that publish reproducible findings cite specific batch numbers in their methods sections, which helps other researchers trace anomalies back to a single production run.

Storage and reconstitution notes. For the lyophilized 2 mg format we supply, we recommend -20 degrees Celsius storage in a desiccated environment. Once reconstituted, aliquots should be stored at -80 degrees Celsius and used within 30 days to minimize degradation.

For a deeper look at how AOD-9604 fits into a rigorous research framework, the full AOD-9604 peptide guide covers documentation standards in more detail.

Why Vendor Certification Criteria Differ Across Suppliers

Not every peptide vendor applies the same quality threshold. Research-grade AOD-9604 peptide sourced from a certified vendor should come with batch-specific COAs, third-party independent testing, documented manufacturing consistency, and responsive technical support. Vendors who rely solely on in-house testing without external verification introduce a conflict of interest into the quality assurance chain.

Here is a reality check: the research peptide marketplace has no single regulatory authority the way pharmaceutical manufacturing does. That places the burden of verification squarely on the researcher and the institution. So what should you actually look for?

Third-party independence. Internal QC testing is not the same as independent third-party analysis. A vendor who sends peptides to an accredited external laboratory for identity and purity confirmation is offering a structurally different level of assurance than one who only runs in-house tests. Ask where the analytical work was performed.

Manufacturing consistency. A single clean COA does not guarantee future lots will match. Vendors with documented quality management systems (QMS) maintain batch-to-batch reproducibility records you can request. Inconsistency between lots is one of the most common sources of unexplained variability in peptide research.

Technical support access. If your lab encounters an unexpected result, you need a supplier whose technical team can speak to their analytical methods, not just forward you a PDF. At PeptideValidation.com, our certification framework evaluates vendors on exactly this criterion because the researchers who use our platform cannot afford to chase answers through a generic support queue.

One of our research customers put it plainly: "PeptideValidation.com is the most comprehensive peptide resource I've found. It has helped me greatly with my research decision making." That kind of feedback reflects what happens when sourcing documentation is treated as a scientific tool, not a compliance formality.

When you compare vendors for AOD-9604 peptide, run the same four-part checklist every time: independent testing, batch-specific COA, QMS documentation, and accessible technical support. If any of those four are missing, keep looking.

Stability, Storage, and Reconstitution: AOD-9604 Compared to Similar Peptides

AOD-9604 peptide in lyophilized form is generally stable for 24 months at -20 degrees Celsius when stored dry and protected from light. Once reconstituted in sterile water or acetic acid solution, shelf life drops significantly. This compares favorably to many linear peptides without disulfide bonds, which tend to oxidize faster in aqueous conditions.

Storage and reconstitution choices directly affect the quality of the research compound you actually use, even if the source material started at 99% purity. This is where the lyophilized 2 mg format has a concrete practical advantage.

Lyophilized versus solution formats. Several vendors sell AOD-9604 peptide pre-dissolved in carrier solutions. While that seems convenient, dissolved peptides are already on the clock. Peptide bonds can hydrolyze slowly in aqueous environments, and the disulfide bridge in AOD-9604 is vulnerable to oxidation at room temperature. Lyophilized powder gives your lab control over when the clock starts.

Reconstitution guidance. For AOD-9604, researchers commonly use sterile bacteriostatic water or a dilute acetic acid solution (0.1 to 1%) as the reconstitution vehicle. The choice of solvent can affect peptide solubility and stability, so it is worth aligning your reconstitution protocol with the specific assay conditions your experiment demands.

Comparing to HGH Fragment 176-191. Because HGH Fragment 176-191 lacks the N-terminal tyrosine, its hydrophilicity profile differs slightly from AOD-9604. In practice, both peptides present similar reconstitution challenges, but they should not be assumed identical in solubility behavior. Treat each compound's solubility characteristics as compound-specific rather than interchangeable.

Temperature sensitivity. Both peptides should avoid repeated freeze-thaw cycles. Aliquot your stock into single-use volumes at the time of reconstitution. Each freeze-thaw cycle risks partial aggregation, which degrades HPLC purity and introduces variability into your assay results.

Common Mistakes Researchers Make When Comparing Peptide Options

The most frequent errors when comparing AOD-9604 peptide to similar compounds include: relying on HPLC purity alone without MS identity confirmation, conflating AOD-9604 with HGH Fragment 176-191 based on sequence similarity, accepting a COA without a batch-specific lot number, and choosing a vendor based on price without verifying third-party testing credentials.

Since comparison is often the first step before a procurement decision, it is worth naming the mistakes I see most often. None of them are exotic, but they each have real consequences for research quality.

Mistake 1: treating HPLC purity as the only metric. A peptide can show 99% purity by HPLC and still be the wrong compound if the identity step was skipped. Purity tells you how much of the main peak is present. MS tells you what that peak actually is. You need both.

Mistake 2: assuming structural similarity equals functional equivalence. AOD-9604 and HGH Fragment 176-191 are close relatives, not identical twins. Because their sequences overlap, some vendors or databases conflate them. Always confirm the exact compound with the exact molecular weight before you design any experimental protocol around its properties.

Mistake 3: ignoring lot-to-lot variability. If your lab runs a multi-week study using peptides sourced at different times, you need to verify that each lot meets the same analytical specifications. A COA from six months ago does not cover the batch you received last Tuesday.

Mistake 4: optimizing for price over documentation. Research-grade AOD-9604 peptide costs more than lower-purity material for a reason. The additional expense pays for the analytical infrastructure (independent HPLC, MS, microbial screening) that stands between your experiment and an undetected contamination event. When the data from a six-month study is at stake, the cost difference between a well-documented and a poorly-documented source is negligible.

Although these mistakes are common, they are also entirely avoidable with the right vendor evaluation framework in place.

Choosing the Right Source: A Practical Checklist for Labs

Before procuring AOD-9604 peptide for research, confirm: (1) the vendor provides batch-specific COAs with MS identity confirmation, (2) purity is verified by an independent third-party laboratory, (3) the peptide ships in lyophilized form with documented storage conditions, and (4) technical support can address compound-specific analytical questions.

Pulling everything together into a usable decision framework is where research purchasing actually gets done. Here is the checklist I walk through when evaluating any peptide source for AOD-9604.

Step 1: Request the most recent batch COA before ordering. A reputable vendor sends it without hesitation. If there is friction around this request, that friction tells you something important.

Step 2: Verify the MS confirmation value. Check that the reported [M+H]+ aligns with the expected 1,979.2 for AOD-9604. Do not accept 'MS: pass' without a number.

Step 3: Confirm the testing laboratory. Ask whether HPLC and MS were performed in-house or by an independent accredited lab. Third-party confirmation removes the conflict of interest that exists when a vendor grades their own work.

Step 4: Confirm the physical format and quantity. For laboratories that run small, controlled experiments, a 2 mg lyophilized unit is the practical standard. It is large enough for multiple reconstitution events but small enough that you are not managing degradation risk across a large stock volume.

Step 5: Evaluate responsiveness before you need help. Send a technical question before you place your first order. How quickly and specifically a vendor responds is a leading indicator of what happens when you actually have a problem mid-study.

If a vendor passes all five steps, you have a defensible, documented sourcing decision that will hold up under institutional review. That is the goal because in peptide research, your compound quality is part of your methodology.

Frequently asked questions